In honor of both National Diabetes Month and the upcoming Thanksgiving holiday, I wanted to share with you the story of a man whom we all owe a debt of gratitude: Dr. Frederick Banting.
Some of you may know this, but World Diabetes Day was chosen to be on November 14 because it is Dr. Banting’s birthday. He was born on November 14, 1891, which meant this year he would have been 118 years old.…
Al Mann, CEO of MannKind Corp., is something of a legend in his own time. He not only founded MiniMed, acquired by Medtronic, but also four other successful medical companies. He’s a billionaire, with his own Biomedical Engineering Institute at the University of Southern California (USC), so we can assume that he’s not just championing the new inhalable insulin product Technosphere (brand name Afresa) as some kind of pipe dream or get-rich-quick scheme.
The guy…
Today, just a sampling of some of the interesting stuff presented at last week’s Diabetes Technology Society meeting, that will be out on the market in … um… some years from now (?):
IN-105 Oral Insulin for Type 2 diabetes – Biocon Limited, apparently India’s premier biotechnology company, has been developing oral insulin tablets for some years now. Positive research results were announced last year. And they’re not just for basal use, either. Studies confirmed…
Read more »
Welcome to another “Where Are They Now?” update on a DiabetesMine Design Challenge entrant. This year, we received a paper entry on PicoSulin, a “revolutionary miniature insulin pump with direct Penfill Cartridge loading.”
I heard from the Geneva, Switzerland-based company last week that their website is now live, presenting in particular a new patch pump model (OmniPod competitor) they’re working on called the PicoPatch.
What’s unique about both products is their tiny size and…
MannKind Corp., the most aggressive company pushing ahead on bringing inhalable insulin to market post the Exubera debacle, took a hit last week when it was forced to announce that a critical marketing partnership didn’t pan out. Investors are now fighting over the company’s future.
As a PWD who watched the whole sordid Exubera story play out with a sad smirk on my face (we all knew the product was too clunky and hard to…
Read more »